We are live on ! Find out more
ATHE

Alterity Therapeutics

12 hedge funds and large institutions have $619K invested in Alterity Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.01%0.01% (-0%)

4% less capital invested

Capital invested by funds: $642K → $619K (-$23K)

8% less funds holding

Funds holding: 1312 (-1)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
2
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

ATHE Hedge Fund Activity: Q3 2018 in Review

12 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2018, worth a combined $619K — down 3.6% from $642K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ATHE and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $24.8K. The largest seller was Susquehanna International Group, cutting an estimated $71.3K.

  • 12 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2018, down from 13 in Q2 2018.
  • Funds reported $619K of Alterity Therapeutics stock for Q3 2018, down 3.6% quarter-over-quarter.
  • 1 fund opened new Alterity Therapeutics positions in Q3 2018 and 2 closed out, a net change of -1 holder.
  • The largest Alterity Therapeutics buyer in Q3 2018 was Morgan Stanley, an estimated $24.8K added.
  • The largest Alterity Therapeutics seller in Q3 2018 was Susquehanna International Group, an estimated $71.3K sold.

Based on aggregated 13F filings for Q3 2018.